ARAF

Across TCGA pan-cancer cohorts, ARAF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARAF data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARAF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARAF expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where ARAF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.796	0.919	.015	15	view →
GBM	DFS	Median	All	0.657	0.822	.016	4	view →
LUAD	DFS	Quartile	III,IV	0.409	0.817	.030	4	view →
PDAC	OS	Quartile	All	0.341	0.605	.025	4	view →
CCRCC	DFS	Quartile	III,IV	1.000	0.744	.035	2	view →
LSCC	DFS	Median	All	0.618	0.791	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARAF–HNSC (OS)

Open the HNSC breakdown →